Fig. 4From: Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosisSerum anti-SCL70 IgG (a), transforming growth factor (TGF)-β (b) and vascular endothelial growth factor (VEGF) (c) levels in patients with systemic sclerosis were decreased after combined plasmapheresis and allogeneic mesenchymal stem cell transplantation therapy.*P < 0.05,**P < 0.01Back to article page